Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety

Samer, Caroline; Daali, Youssef; Wagner, Michel; Hopfgartner, Gérard; B. Eap, Chin; Rebsamen, M.; Rossier, MF; Hochstrasser, D; Dayer, Pierre; Desmeules, JA

doi:10.1111/j.1476-5381.2010.00709.x

Public

Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety

Published in British Journal of Pharmacology • Mar 2, 2010

Authors:

Caroline Samer

Youssef Daali

Michel Wagner

Abstract

BACKGROUND AND PURPOSE: The major drug-metabolizing enzymes for the oxidation of oxycodone are CYP2D6 and CYP3A. A high interindividual variability in the activity of these enzymes because of genetic polymorphisms and/or drug-drug interactions is well established. The possible role of an active meta...

Subject

Oxycodone

Pharmacodynamics

Pharmacology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!